This implied that the increase in the ruthenium sensitivity in BRCA1 defective breast cancer cells might be related to a dysfunctional BRCA1 that is unable to repair DNA damage produced by ruthenium treatment, and ultimately led to breast cancer cell death[51]. Here, BRCA1 is linked to breast carcinoma.